LRP1 silencing [26], (Figure S1A) blocked GBM cell motility in a manner similar to NPGA or Hsp90 antibody treatments, with no further suppression elicited by NPGA (Figure 1B). The gene discussed is HSP90AA1; the disease is glioblastoma.